# Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention

Study · id `cardio:ct-nct06692140` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06692140](<https://clinicaltrials.gov/study/NCT06692140>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06692140

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3150 participants.

## Technical summary

Registry record NCT06692140. Randomized; single masking; primary purpose treatment. Start 2024-11-16 (actual); primary completion 2028-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 3150 participants (planned count; ClinicalTrials.gov record NCT06692140, source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)
- Started: 2024-11-16 (actual) (ClinicalTrials.gov record NCT06692140, source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)
- Primary completion: 2028-07-01 (anticipated) (ClinicalTrials.gov record NCT06692140, source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)
- Completion: 2032-07-01 (anticipated) (ClinicalTrials.gov record NCT06692140, source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06692140, source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06692140-2026-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention
- Acronym: SORT OUT XII
- Condition: Ischemia, Myocardial
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention (PCI)
- Intervention (Device): Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
- Intervention (Device): PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
- Lead sponsor: Odense University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Odense University Hospital (`cardio:org-odense-university-hospital`)

## Provenance

Content hash: e2a0ab733a17b6eaa3339b1b523bbd51a5cbeaccb2dc125428869290541decdc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
